G. Peterson

发表

Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications

M. Markman, K. Webster, B. Kulp, 2005, Cancer investigation.

Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

M. Markman, J. Belinson, K. Webster, 2004, Journal of Cancer Research and Clinical Oncology.

Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.

P. Elson, M. Markman, J. Belinson, 2003, Gynecologic oncology.

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

M. Markman, J. Belinson, K. Webster, 2003, Gynecologic oncology.

Weekly carboplatin as a strategy to prevent severe treatment-related emesis.

M. Markman, A. Kennedy, B. Kulp, 2000, Gynecologic Oncology.

Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

M. Markman, J. Belinson, K. Webster, 2003, Journal of Cancer Research and Clinical Oncology.

Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.

A. Kennedy, J. Belinson, K. Webster, 1999, Gynecologic oncology.

Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

M. Markman, J. Belinson, A. Kennedy, 1998, Journal of Cancer Research and Clinical Oncology.

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

G. Sutton, M. Markman, J. Hurteau, 1998, Gynecologic oncology.

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.

M. Markman, A. Kennedy, J. Belinson, 1997, Gynecologic oncology.

Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.

M. Markman, J. Belinson, K. Webster, 2003, Gynecologic oncology.

Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

M. Markman, A. Kennedy, J. Belinson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer.

M. Markman, A. Kennedy, J. Belinson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paclitaxel-Assoc iated H ypersensitivity R eactions: Experience o f t he G ynecologic O ncology P rogram o f t he Cleveland C linic C ancer C enter

M. Markman, J. Belinson, A. Kennedy, 2000 .

Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

M. Markman, A. Kennedy, J. Belinson, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors.

A. Kennedy, J. Belinson, K. Webster, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.

M. Markman, D. Uyar, J. Belinson, 2004, Gynecologic oncology.

Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.

M. Markman, J. Belinson, K. Webster, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.

L. Rybicki, M. Markman, J. Belinson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.

M. Markman, A. Kennedy, J. Belinson, 1996, Gynecologic oncology.

The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.

M. Markman, A. Kennedy, J. Belinson, 1998, Gynecologic oncology.

Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports.

M. Markman, J. Belinson, A. Kennedy, 2002, Gynecologic oncology.

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

M. Markman, A. Kennedy, J. Belinson, 1996, Gynecologic oncology.

Experience with pelvic washings in stage I and II endometrial carcinoma.

A. Kennedy, K. Webster, G. Peterson, 1987 .

Clinical features of hypersensitivity reactions to carboplatin.

P. Elson, A. Kennedy, J. Belinson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma

C. Michener, M. Markman, K. Webster, 2005, Journal of Cancer Research and Clinical Oncology.

Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia

M. Markman, J. Belinson, A. Kennedy, 2000, Journal of Cancer Research and Clinical Oncology.

Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias.

M. Markman, A. Kennedy, J. Belinson, 1999, Gynecologic oncology.

Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies

M. Markman, J. Belinson, A. Kennedy, 2001, Journal of Cancer Research and Clinical Oncology.

Expanded E xperience W ith a n I ntradermal S kin T est t o Predict f or t he P resence o r A bsence o f C arboplatin Hypersensitivity

M. Markman, J. Belinson, K. Webster, 2003 .

Gastrointestinal toxicity is not a major complication of standard dose paclitaxel therapy.

M. Markman, A. Kennedy, J. Belinson, 1999, Gynecologic oncology.

Clinical F eatures o f H ypersensitivity Reactions t o C arboplatin

P. Elson, M. Markman, J. Belinson, 1999 .

Carboplatin S kin T esting: A S kin-Testing P rotocol f or Predicting H ypersensitivity t o C arboplatin C hemotherapy

M. Markman, B. Kulp, G. Peterson, 2001 .

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

M. Markman, J. Belinson, K. Webster, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.

Maurie Markman, M. Markman, Robert J Kim, 2005, Gynecologic oncology.

Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis

M. Markman, J. Belinson, A. Kennedy, 2005, Journal of Cancer Research and Clinical Oncology.

Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.

M. Markman, B. Kulp, G. Peterson, 2002, Gynecologic oncology.

Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactions

Maurie Markman, M. Markman, J. Belinson, 1999, Journal of Cancer Research and Clinical Oncology.

Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.

M. Markman, B. Kulp, G. Peterson, 2004, Gynecologic oncology.

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.

M. Markman, B. Kulp, G. Peterson, 2003, Gynecologic oncology.

Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions.

M. Markman, A. Kennedy, J. Belinson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leuprolide in the treatment of endometrial cancer.

M. Markman, A. Kennedy, J. Belinson, 1997, Gynecologic Oncology.

Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.

M. Markman, A. Kennedy, J. Belinson, 1997, Seminars in oncology.